TY - JOUR
T1 - Oseltamivir for influenza
AU - Jones, Mark
AU - Hama, Rokuro
AU - Del Mar, Chris
N1 - Funding Information:
MJ, RH, and CDM are co-recipients of a UK National Institute for Health Research (NIHR) grant (HTA—10/80/01). RH wrote two books on the harm of Tamiflu and antipyretics and provided scientific opinions and expert testimony on 14 adverse reaction cases related to oseltamivir. CDM was a Board member of Bond University Research Innovations Pty Ltd and Bond University Research Development Pty Ltd, receives fees for editorial and guideline developmental work and royalties from books, and is in receipt of institutional grants from NHMRC (Australia), NIHR (UK) and Health Technology Assessment (UK), and from a private donor (for support of the editorial base of the Cochrane Acute Respiratory Infections Group).
PY - 2015/9/19
Y1 - 2015/9/19
N2 - [Extract] In their Article (May 2, p 1729) on oseltamivir treatment for influenza, Joanna Dobson and colleagues reported both fewer admittances to hospital for those treated with oseltamivir in the subgroup of patients classified as infected and fewer lower respiratory tract complications in patients treated with antibiotics as a surrogate for severity than in placebo recipients. However, our Cochrane review found insufficient evidence of a difference between groups for complications classified as serious or leading to patient withdrawal, or for rate of admittance to hospital.
AB - [Extract] In their Article (May 2, p 1729) on oseltamivir treatment for influenza, Joanna Dobson and colleagues reported both fewer admittances to hospital for those treated with oseltamivir in the subgroup of patients classified as infected and fewer lower respiratory tract complications in patients treated with antibiotics as a surrogate for severity than in placebo recipients. However, our Cochrane review found insufficient evidence of a difference between groups for complications classified as serious or leading to patient withdrawal, or for rate of admittance to hospital.
UR - http://www.scopus.com/inward/record.url?scp=84942154585&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(15)00200-7
DO - 10.1016/S0140-6736(15)00200-7
M3 - Letter
C2 - 26461897
SN - 0140-6736
VL - 386
SP - 1133
EP - 1134
JO - The Lancet
JF - The Lancet
IS - 9999
ER -